Ushio Y, Kochi M, Kuratsu J, Itoyama Y, Marubayashi T
Department of Neurosurgery, Kumamoto University Medical School, Kumamoto, Japan.
J Neurosurg. 1999 Jan;90(1):133-7. doi: 10.3171/jns.1999.90.1.0133.
The authors evaluated the effect of adjuvant therapy (preoperative chemotherapy combined with radiotherapy) followed by radical tumor removal in the treatment of children with primary intracranial yolk sac tumor, embryonal carcinoma, or mixed germ cell tumors containing yolk sac tumor components. Between 1988 and 1995, five consecutive patients were treated with adjuvant therapy followed by total tumor removal. The diagnosis was based on markedly elevated concentrations of serum alpha-fetoprotein (AFP) and/or beta-human chorionic gonadotropin (beta-HCG) in four children and the results of biopsy sampling in one child. The chemotherapy regimen consisted of cisplatin (20 mg/m2) and etoposide (60 mg/m2) daily for 5 days (one course) given three times at 4-weeks intervals. Radiotherapy consisted of 30 to 40 Gy to the whole brain or an area including all ventricles and a 15- to 20-Gy boost to the tumor site. Spinal radiation of 25 Gy was added in one patient. In all patients the serum level of AFP and beta-HCG gradually decreased during the adjuvant therapy and disappeared completely on its completion. In two of the five patients the tumor disappeared as well. In the other three patients the tumor size was moderately or markedly reduced and the remaining tumor was totally removed; there were no neurological deficits. Chemotherapy was maintained after the initial treatment and was repeated every 2 to 4 months for less than 2 years. All children are alive and well without recurrence at 33 to 118 months (average 88 months) after the start of adjuvant therapy. Our preliminary results indicate that adjuvant therapy consisting of combination chemotherapy with cisplatin and etoposide and concomitant radiotherapy, followed by removal of the tumor, is highly effective in the treatment of pediatric patients with primary intracranial yolk sac tumor, embryonal carcinoma, or mixed germ cell tumors containing yolk sac tumor components.
作者评估了辅助治疗(术前化疗联合放疗)继以根治性肿瘤切除对原发性颅内卵黄囊瘤、胚胎癌或含有卵黄囊瘤成分的混合性生殖细胞肿瘤患儿的治疗效果。1988年至1995年期间,连续5例患者接受了辅助治疗,随后进行了肿瘤全切。4例患儿的诊断依据是血清甲胎蛋白(AFP)和/或β-人绒毛膜促性腺激素(β-HCG)浓度显著升高,1例患儿的诊断依据是活检取样结果。化疗方案为顺铂(20mg/m²)和依托泊苷(60mg/m²)每日给药,共5天(1个疗程),每4周重复3次。放疗包括全脑或包括所有脑室的区域给予30至40Gy,肿瘤部位给予15至20Gy的追加剂量。1例患者还接受了25Gy的脊髓放疗。在所有患者中,辅助治疗期间血清AFP和β-HCG水平逐渐下降,并在治疗结束时完全消失。5例患者中有2例肿瘤也消失了。另外3例患者肿瘤大小中度或明显缩小,残余肿瘤被完全切除;无神经功能缺损。初始治疗后维持化疗,每2至4个月重复1次,持续时间少于2年。所有患儿在辅助治疗开始后33至118个月(平均88个月)均存活且情况良好,无复发。我们的初步结果表明,由顺铂和依托泊苷联合化疗及同步放疗组成的辅助治疗,继以肿瘤切除,在治疗原发性颅内卵黄囊瘤、胚胎癌或含有卵黄囊瘤成分的混合性生殖细胞肿瘤的儿科患者中非常有效。